(APGE) Apogee Therapeutics, Common - Overview
Stock: Monoclonal Antibodies, Atopic Dermatitis, Asthma, Eosinophilic Esophagitis
| Risk 5d forecast | |
|---|---|
| Volatility | 66.8% |
| Relative Tail Risk | -6.47% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.89 |
| Alpha | 33.47 |
| Character TTM | |
|---|---|
| Beta | 1.128 |
| Beta Downside | 0.647 |
| Drawdowns 3y | |
|---|---|
| Max DD | 58.75% |
| CAGR/Max DD | 1.12 |
Description: APGE Apogee Therapeutics, Common January 13, 2026
Apogee Therapeutics (NASDAQ:APGE) is a clinical-stage biotech focused on developing extended-half-life monoclonal antibodies for Type 2 inflammatory diseases, including atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), and COPD. Its lead candidate, APG777, is a subcutaneous mAb currently in Phase 2 for AD and in Phase 1 for asthma/EoE, while a pipeline of preclinical and early-stage assets (APG279, APG990, APG333, APG808) targets the same therapeutic space.
Key market-level observations: (1) The global AD biologics market is projected to exceed $5 billion by 2028, driven by rising prevalence and limited long-term steroid options; (2) In 2023, U.S. biotech R&D spend grew ~7 % YoY, indicating ample capital for companies like APGE to fund early trials, but also intensifying competition for investor dollars; (3) As of the latest filing, APGE reported ~ $120 million in cash and equivalents, giving it an estimated 12-month runway assuming current burn rates, though this is highly sensitive to trial outcomes and financing needs.
For a deeper, data-driven view of APGE’s valuation dynamics, you may find it useful to explore the analyst tools on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -253.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.38 > 0.02 and ΔFCF/TA -20.61 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.37 > 3% & CFO -232.5m > Net Income -253.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 15.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (58.8m) vs 12m ago 3.48% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.02% > 50% (prev 0.0%; Δ 0.02% > 0%) |
| Interest Coverage Ratio: -11.71 > 6 (EBITDA TTM -276.0m / Interest Expense TTM -23.7m) |
Altman Z'' -12.87
| A: 0.81 (Total Current Assets 540.1m - Total Current Liabilities 34.0m) / Total Assets 626.2m |
| B: -0.79 (Retained Earnings -492.4m / Total Assets 626.2m) |
| C: -0.40 (EBIT TTM -277.1m / Avg Total Assets 701.2m) |
| D: -12.34 (Book Value of Equity -491.3m / Total Liabilities 39.8m) |
| Altman-Z'' Score: -12.87 = D |
What is the price of APGE shares?
Over the past week, the price has changed by -4.99%, over one month by -20.46%, over three months by +13.17% and over the past year by +49.47%.
Is APGE a buy, sell or hold?
- StrongBuy: 9
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the APGE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 104.5 | 67.9% |
| Analysts Target Price | 104.5 | 67.9% |
| ValueRay Target Price | 76 | 22% |
APGE Fundamental Data Overview February 02, 2026
Revenue TTM = 130.0k USD
EBIT TTM = -277.1m USD
EBITDA TTM = -276.0m USD
Long Term Debt = 9.85m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 4.08m USD (from shortTermDebt, last quarter)
Debt = 9.85m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -98.1m USD (from netDebt column, last quarter)
Enterprise Value = 3.96b USD (4.48b + Debt 9.85m - CCE 527.3m)
Interest Coverage Ratio = -11.71 (Ebit TTM -277.1m / Interest Expense TTM -23.7m)
EV/FCF = -16.66x (Enterprise Value 3.96b / FCF TTM -237.6m)
FCF Yield = -6.00% (FCF TTM -237.6m / Enterprise Value 3.96b)
FCF Margin = -182.7k% (FCF TTM -237.6m / Revenue TTM 130.0k)
Net Margin = -195.1k% (Net Income TTM -253.7m / Revenue TTM 130.0k)
Gross Margin = -674.6% ((Revenue TTM 130.0k - Cost of Revenue TTM 1.01m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 6.32 (Enterprise Value 3.96b / Total Assets 626.2m)
Interest Expense / Debt = -240.2% (Interest Expense -23.7m / Debt 9.85m)
Taxrate = 21.0% (US default 21%)
NOPAT = -218.9m (EBIT -277.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 15.86 (Total Current Assets 540.1m / Total Current Liabilities 34.0m)
Debt / Equity = 0.02 (Debt 9.85m / totalStockholderEquity, last quarter 586.3m)
Debt / EBITDA = 0.36 (negative EBITDA) (Net Debt -98.1m / EBITDA -276.0m)
Debt / FCF = 0.41 (negative FCF - burning cash) (Net Debt -98.1m / FCF TTM -237.6m)
Total Stockholder Equity = 649.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -36.18% (Net Income -253.7m / Total Assets 626.2m)
RoE = -39.09% (Net Income TTM -253.7m / Total Stockholder Equity 649.0m)
RoCE = -42.06% (EBIT -277.1m / Capital Employed (Equity 649.0m + L.T.Debt 9.85m))
RoIC = -30.19% (negative operating profit) (NOPAT -218.9m / Invested Capital 725.2m)
WACC = 10.05% (E(4.48b)/V(4.49b) * Re(10.07%) + (debt cost/tax rate unavailable))
Discount Rate = 10.07% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 7.72%
Fair Price DCF = unknown (Cash Flow -237.6m)
EPS Correlation: 45.79 | EPS CAGR: 41.48% | SUE: 2.34 | # QB: 1
Revenue Correlation: 21.84 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.12 | Chg30d=+0.015 | Revisions Net=+1 | Analysts=7
EPS next Year (2026-12-31): EPS=-4.89 | Chg30d=+0.080 | Revisions Net=-1 | Growth EPS=-16.4% | Growth Revenue=+0.0%